Four insights:
1. The addition of Arkis’ neurosurgical devices will enhance Integra’s position in the neurocritical care market; a core focus area for the company.
2. The acquisition provides more therapeutic choices in catheter obstruction and bacterial colonization, which present difficulties for healthcare teams in managing the external drainage of cerebrospinal fluid in neurocritical care.
3. Arkis’ portfolio includes the CererbroFlo external ventricular drainage catheter, which is designed to decrease the potential for catheter obstruction due to thrombus formation.
4. Integra LifeSciences does not anticipate the acquisition to have a material financial impact this year.
More articles on devices:
Boston Scientific unveils venture with Mayo Clinic — 5 details
Zimmer Biomet CEO Bryan Hanson clears the air on CFO transition, focuses on robotics during Q2 earnings call
MiRus receives FDA clearance for cervical plate device — 3 insights
